An initial drop in eGFR (driven by hemodynamic changes in the glomerular circulation) is seen when SGLT2 inhibitors are initiated; however, there has been no confirmed increased risk of acute kidney injury (AKI) occurrence, and conversely, they have been seen to reduce the risk of AKI in patients with T2DM [66]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.